MaaT Pharma SA (MAAT.PA)
EUR 5.86
(1.38%)
EUR 5.86
(1.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.59 Million EUR | 73.37% |
| 2022 | 14.64 Million EUR | 51.02% |
| 2021 | 9.69 Million EUR | 84.64% |
| 2020 | 5.25 Million EUR | 5.8% |
| 2019 | 4.96 Million EUR | 12.74% |
| 2018 | 4.4 Million EUR | 234.5% |
| 2017 | 1.31 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.97 Million EUR | 19.5% |
| 2024 Q2 | 6.97 Million EUR | 0.0% |
| 2023 Q1 | 4.81 Million EUR | -46.25% |
| 2023 Q2 | 12.16 Million EUR | 152.55% |
| 2023 FY | 25.39 Million EUR | 73.37% |
| 2023 Q3 | 5.83 Million EUR | -52.05% |
| 2023 Q4 | 5.83 Million EUR | -0.03% |
| 2022 FY | 14.64 Million EUR | 51.02% |
| 2022 Q4 | 8.96 Million EUR | 173.25% |
| 2022 Q3 | 3.28 Million EUR | -65.09% |
| 2022 Q2 | 9.39 Million EUR | 140.95% |
| 2022 Q1 | 3.9 Million EUR | -38.58% |
| 2021 Q4 | 6.35 Million EUR | 144.32% |
| 2021 FY | 9.69 Million EUR | 84.64% |
| 2021 Q3 | 2.59 Million EUR | -51.97% |
| 2021 Q2 | 5.41 Million EUR | 149.24% |
| 2021 Q1 | 2.17 Million EUR | -45.86% |
| 2020 FY | 5.25 Million EUR | 5.8% |
| 2020 Q3 | 975.49 Thousand EUR | -69.65% |
| 2020 Q2 | 3.21 Million EUR | 96.33% |
| 2020 Q1 | 1.63 Million EUR | 0.0% |
| 2020 Q4 | 4.01 Million EUR | 311.07% |
| 2019 FY | 4.96 Million EUR | 12.74% |
| 2018 FY | 4.4 Million EUR | 234.5% |
| 2017 FY | 1.31 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -417.07% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 83.044% |
| Adocia SA | 15.62 Million EUR | -38.192% |
| Aelis Farma SA | 18.81 Million EUR | -14.767% |
| Biophytis S.A. | 14.33 Million EUR | -50.687% |
| Advicenne S.A. | 8.21 Million EUR | -162.909% |
| genOway Société anonyme | 16.73 Million EUR | -29.034% |
| IntegraGen SA | 5.35 Million EUR | -303.512% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1280.441% |
| Neovacs S.A. | 10.34 Million EUR | -108.807% |
| NFL Biosciences SA | 4.37 Million EUR | -393.742% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -681.164% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -1157.185% |
| Sensorion SA | 27.05 Million EUR | 20.166% |
| Theranexus Société Anonyme | 3 Million EUR | -618.739% |
| TME Pharma N.V. | 5.49 Million EUR | -292.905% |
| Valbiotis SA | 9.86 Million EUR | -118.847% |
| TheraVet SA | 1.64 Million EUR | -1213.497% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -6.289% |
| DBV Technologies S.A. | 89.4 Million EUR | 75.843% |
| Genfit S.A. | 54.8 Million EUR | 60.59% |
| GeNeuro SA | 14.35 Million EUR | -50.432% |
| Innate Pharma S.A. | 64.57 Million EUR | 66.551% |
| Inventiva S.A. | 120.18 Million EUR | 82.03% |
| MedinCell S.A. | 32.92 Million EUR | 34.396% |
| Nanobiotix S.A. | 58.92 Million EUR | 63.348% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 8.44% |
| Poxel S.A. | 28.76 Million EUR | 24.916% |
| GenSight Biologics S.A. | 32.66 Million EUR | 33.87% |
| Transgene SA | 31.23 Million EUR | 30.844% |
| Valneva SE | 134.92 Million EUR | 83.992% |